Carolinas HealthCare System

Research and Clinical Trials

Brief Description Principal Investigator
To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug. Kim, Edward Sanghyun
In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types: HPV-positive (SCCHN), HPV-negative (SCCHN), Merkel Cell Carcinoma, Cervical, vaginal, or vulvar cancers. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy and combination therapy of Nivolumab and Ipilimumab in subjects with the following diseases: Metastatic or recurrent nasophary Amin, Asim
Primary: To compare progression free survival as determined by independent radiology committee and overall survival of nivolumab combined with ipimumab to EXTREME regimen as first line treatment in subjects with recurrent or metastatic SCCHN.
Secondary: To compare the objective response rate, as determined by IRC.To compare time to symptom deterioration as assessed using the 10-item Functional Assessment of Cancer Therapy-Head & Neck Symptom Index. To evaluated whether PD-L1 expression is a pr
Sumrall, Ashley Love
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.

II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.

III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
Kaplan, Joel Adam
Overall survival: From randomization to date of death or last follow-up. Moeller, Benjamin James
Close